Toradol — Competitive Intelligence Brief

Toradol (KETOROLAC) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cyclooxygenase Inhibitor. Area: Pain.

marketed Cyclooxygenase Inhibitor Prostaglandin G/H synthase 1 Pain Small molecule

Target snapshot

Toradol (KETOROLAC).

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Toradol TARGET	KETOROLAC		marketed	Cyclooxygenase Inhibitor	Prostaglandin G/H synthase 1	1989-01-01
Joicela	LUMIRACOXIB	Novartis Pharmaceuticals UK Limited	marketed	lumiracoxib	Prostaglandin G/H synthase 1	2005-01-01
Etocox	ETORICOXIB		marketed	etoricoxib	Mitogen-activated protein kinase 14, Prostaglandin E2 receptor EP2 subtype, Prostaglandin G/H synthase 1	2002-01-01
Colazal	BALSALAZIDE	Valeant Pharms Intl	marketed	Aminosalicylate	Prostaglandin G/H synthase 1	2000-01-01
DEXIBUPROFEN	DEXIBUPROFEN		marketed	dexibuprofen	Prostaglandin G/H synthase 1	1994-01-01
(+)-Ketoprofen	DEXKETOPROFEN		marketed	Nonsteroidal Anti-inflammatory Drug [EPC]	Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2	1994-01-01
MOFEZOLAC	MOFEZOLAC		marketed	mofezolac	Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2, Prostaglandin G/H synthase 1	1994-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cyclooxygenase Inhibitor class)

1. · 1 drug in this class